Cargando…

Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan

The accurate and prompt diagnosis of SARS-CoV-2 infection is required for the control and treatment of the coronavirus infection disease 2019 (COVID-19). In this study, we aimed to investigate the time courses of the anti-severe acute corona respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM and Ig...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Yuki, Kurano, Makoto, Morita, Yoshifumi, Shimura, Takuya, Yokoyama, Rin, Qian, Chungen, Xia, Fuzhen, He, Fan, Kishi, Yoshiro, Okada, Jun, Yoshikawa, Naoyuki, Nagura, Yutaka, Okazaki, Hitoshi, Moriya, Kyoji, Seto, Yasuyuki, Kodama, Tatsuhiko, Yatomi, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854735/
https://www.ncbi.nlm.nih.gov/pubmed/33531605
http://dx.doi.org/10.1038/s41598-021-82428-5
_version_ 1783646145654816768
author Nakano, Yuki
Kurano, Makoto
Morita, Yoshifumi
Shimura, Takuya
Yokoyama, Rin
Qian, Chungen
Xia, Fuzhen
He, Fan
Kishi, Yoshiro
Okada, Jun
Yoshikawa, Naoyuki
Nagura, Yutaka
Okazaki, Hitoshi
Moriya, Kyoji
Seto, Yasuyuki
Kodama, Tatsuhiko
Yatomi, Yutaka
author_facet Nakano, Yuki
Kurano, Makoto
Morita, Yoshifumi
Shimura, Takuya
Yokoyama, Rin
Qian, Chungen
Xia, Fuzhen
He, Fan
Kishi, Yoshiro
Okada, Jun
Yoshikawa, Naoyuki
Nagura, Yutaka
Okazaki, Hitoshi
Moriya, Kyoji
Seto, Yasuyuki
Kodama, Tatsuhiko
Yatomi, Yutaka
author_sort Nakano, Yuki
collection PubMed
description The accurate and prompt diagnosis of SARS-CoV-2 infection is required for the control and treatment of the coronavirus infection disease 2019 (COVID-19). In this study, we aimed to investigate the time courses of the anti-severe acute corona respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM and IgG titers and to evaluate the sensitivity and specificity of such tests according to the specific day after the onset of COVID-19 among a patient population in Japan. We measured the titers of SARS-CoV-2 IgM and IgG in sera from 105 subjects, including 26 symptomatic COVID-19 patients, using chemiluminescent immunoassay (CLIA) methods utilizing magnetic beads coated with SARS-CoV-2 nucleocapsid protein and spike protein. The results of a ROC analysis suggested the possibility that the cutoff values in Japan might be lower than the manufacturer’s reported cutoff (10 AU/mL): 1  AU/mL for IgM and 5  AU/mL for IgG. The sensitivity of the test before Day 8 after symptom onset was less than 50%; at Days 9–10, however, we obtained a much higher sensitivity of 81.8% for both IgM and IgG. At 15 days or later after symptom onset, the SARS-CoV-2 IgG test had a sensitivity of 100%. These results suggest that if the number of days since disease onset is taken into consideration, these antibody tests could be very useful for the diagnosis of COVID-19 and similar diseases.
format Online
Article
Text
id pubmed-7854735
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78547352021-02-04 Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan Nakano, Yuki Kurano, Makoto Morita, Yoshifumi Shimura, Takuya Yokoyama, Rin Qian, Chungen Xia, Fuzhen He, Fan Kishi, Yoshiro Okada, Jun Yoshikawa, Naoyuki Nagura, Yutaka Okazaki, Hitoshi Moriya, Kyoji Seto, Yasuyuki Kodama, Tatsuhiko Yatomi, Yutaka Sci Rep Article The accurate and prompt diagnosis of SARS-CoV-2 infection is required for the control and treatment of the coronavirus infection disease 2019 (COVID-19). In this study, we aimed to investigate the time courses of the anti-severe acute corona respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM and IgG titers and to evaluate the sensitivity and specificity of such tests according to the specific day after the onset of COVID-19 among a patient population in Japan. We measured the titers of SARS-CoV-2 IgM and IgG in sera from 105 subjects, including 26 symptomatic COVID-19 patients, using chemiluminescent immunoassay (CLIA) methods utilizing magnetic beads coated with SARS-CoV-2 nucleocapsid protein and spike protein. The results of a ROC analysis suggested the possibility that the cutoff values in Japan might be lower than the manufacturer’s reported cutoff (10 AU/mL): 1  AU/mL for IgM and 5  AU/mL for IgG. The sensitivity of the test before Day 8 after symptom onset was less than 50%; at Days 9–10, however, we obtained a much higher sensitivity of 81.8% for both IgM and IgG. At 15 days or later after symptom onset, the SARS-CoV-2 IgG test had a sensitivity of 100%. These results suggest that if the number of days since disease onset is taken into consideration, these antibody tests could be very useful for the diagnosis of COVID-19 and similar diseases. Nature Publishing Group UK 2021-02-02 /pmc/articles/PMC7854735/ /pubmed/33531605 http://dx.doi.org/10.1038/s41598-021-82428-5 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Nakano, Yuki
Kurano, Makoto
Morita, Yoshifumi
Shimura, Takuya
Yokoyama, Rin
Qian, Chungen
Xia, Fuzhen
He, Fan
Kishi, Yoshiro
Okada, Jun
Yoshikawa, Naoyuki
Nagura, Yutaka
Okazaki, Hitoshi
Moriya, Kyoji
Seto, Yasuyuki
Kodama, Tatsuhiko
Yatomi, Yutaka
Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan
title Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan
title_full Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan
title_fullStr Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan
title_full_unstemmed Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan
title_short Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan
title_sort time course of the sensitivity and specificity of anti-sars-cov-2 igm and igg antibodies for symptomatic covid-19 in japan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854735/
https://www.ncbi.nlm.nih.gov/pubmed/33531605
http://dx.doi.org/10.1038/s41598-021-82428-5
work_keys_str_mv AT nakanoyuki timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT kuranomakoto timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT moritayoshifumi timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT shimuratakuya timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT yokoyamarin timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT qianchungen timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT xiafuzhen timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT hefan timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT kishiyoshiro timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT okadajun timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT yoshikawanaoyuki timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT nagurayutaka timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT okazakihitoshi timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT moriyakyoji timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT setoyasuyuki timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT kodamatatsuhiko timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan
AT yatomiyutaka timecourseofthesensitivityandspecificityofantisarscov2igmandiggantibodiesforsymptomaticcovid19injapan